- Home
- MPW vs CPRX Comparison
MPW vs CPRX Comparison
Compare MPW & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPW
- CPRX
- Stock Information
- Founded
- MPW 2003
- CPRX 2002
- Country
- MPW United States
- CPRX United States
- Employees
- MPW N/A
- CPRX N/A
- Industry
- MPW Real Estate Investment Trusts
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- MPW Real Estate
- CPRX Health Care
- Exchange
- MPW Nasdaq
- CPRX Nasdaq
- Market Cap
- MPW 2.9B
- CPRX 2.9B
- IPO Year
- MPW 2005
- CPRX 2006
- Fundamental
- Price
- MPW $5.81
- CPRX $23.68
- Analyst Decision
- MPW Hold
- CPRX Strong Buy
- Analyst Count
- MPW 6
- CPRX 5
- Target Price
- MPW $5.42
- CPRX $32.60
- AVG Volume (30 Days)
- MPW 9.1M
- CPRX 1.4M
- Earning Date
- MPW 10-30-2025
- CPRX 11-05-2025
- Dividend Yield
- MPW 5.55%
- CPRX N/A
- EPS Growth
- MPW N/A
- CPRX 44.94
- EPS
- MPW N/A
- CPRX 1.71
- Revenue
- MPW $1,009,160,000.00
- CPRX $578,196,000.00
- Revenue This Year
- MPW N/A
- CPRX $16.59
- Revenue Next Year
- MPW $9.68
- CPRX $8.42
- P/E Ratio
- MPW N/A
- CPRX $13.71
- Revenue Growth
- MPW 52.52
- CPRX 25.56
- 52 Week Low
- MPW $3.51
- CPRX $19.05
- 52 Week High
- MPW $6.34
- CPRX $26.58
- Technical
- Relative Strength Index (RSI)
- MPW 72.49
- CPRX 69.16
- Support Level
- MPW $4.98
- CPRX $22.23
- Resistance Level
- MPW $5.24
- CPRX $23.92
- Average True Range (ATR)
- MPW 0.17
- CPRX 0.80
- MACD
- MPW 0.08
- CPRX 0.09
- Stochastic Oscillator
- MPW 98.94
- CPRX 91.23
About MPW Medical Properties Trust Inc. common stock
Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. The group's geographic areas are the United States, the United Kingdom, and All other countries.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).